The recognition that PI3K signaling was aberrantly activated in acute myeloid leukemia (AML) owing to somatic mutations in PIK3Ca, along with the core function of this axis in forcing leukemic cell resistance to apoptosis, paved the way for the recognition of PI3K inhibitors as key elements in the field of AML therapy [4]. Here, PIK3CA is linked to acute myeloid leukemia.